APPENDICES. A systematic review and economic model of the ...

More documents

Recommendations

Info

170 Appendix 2 14. (person trade off* or person tradeoff* or standard gamble* or time trade off or time tradeoff or tto or willingness pay or disutilities or disutility or daly or disability adjusted life or qaly* or qualy* or quality adjusted life or quality life) in ti,ab,de,kc,mj,mn 15. (life quality or qwb or quality wellbeing or quality well being or index well being or index wellbeing or factor analysis or preference based or health status or health state*) in ti,ab,de,kc,mj,mn 16. (state near (value or values or valuing or valued)) in ti,ab,de,kc,mj,mn 17. (sickness Impact Profile or hspv or quality adjusted life year or utilit* approach* or health gain or hui or hui2 or hui 2 or hui3 or hui 3) in ti,ab,de,kc,mj,mn 18. (categor* scal* or linear scal* or linear analog* scal* or visual scal* or magnitude estimat* or multiattribute* health) in ti,ab,de,kc,mj,mn 19. (multi attribute* health or health measurement* or health survey questionnaire* or general health questionnaire* or ghq or multiattribute* theor* or multi attribute* theor* or multiattribute* analys* or multi attribute* analys* or classification illness state* or health utilit* or multiattribute* utilit* or multi attribute* utilit* or theory utilit*) in ti,ab,de,kc,mj,mn 20. #13 or #14 or #15 or #16 or #17 or #18 21. #19 and #12 This retrieved 69 records. Social Science Citation Index (SSCI) (1981–2004) and Science Citation Index (SCI) (1981–2004) Searched: 22 June 2004 on ISI Web of Knowledge via MIMAS at http://wos.mimas.ac.uk/ #1 TS=((Behav* and Hyperactiv*) OR (Cogniti* and Hyperactiv*) OR adhd OR attention deficit* OR Minimal brain damage* OR minimal brain dysfunction* OR hyperkinetic* OR conduct disorder* OR oppositional defian* OR impulsivity OR inattent*) #2 TS=(sf 36 or sf 36 or eq5d or eq 5d or euroqol or short form 36 or shortform 36 or sf thirtysix or sf thirty six or shortform thirtysix or shortform thirty six or short form thirtysix or short form thirty six or hrql or hrqol or qol or hql or hqol #3 TS=(health status or health state* or sickness Impact Profile or hspv or quality adjusted life year or utilit* approach* or health gain or hui or hui2 or hui 2 or hui3 or hui 3 or categor* scal* or linear scal* or linear analog* scal* or visual scal* or magnitude estimat* or multiattribute* health) #4 TS=(hye or hyes or health* year* equivalent* or rosser or person trade off* or person tradeoff* or standard gamble* or time trade off or time tradeoff or tto or willingness pay or disutilities or disutility or daly or disability adjusted life or qaly* or qualy* or quality adjusted life or quality life or life quality or qwb or quality wellbeing or quality well being or index well being or index wellbeing or preference based) #5 TS=(multi attribute* health or health measurement* or health survey questionnaire* or general health questionnaire* or ghq or multiattribute* theor* or multi attribute* theor* or multiattribute* analys* or multi attribute* analys* or classification illness state* or multiattribute* utilit* or multi attribute* utilit* or theory utilit*) #6 TS=state same (value or values or valuing or valued) #7 TS=(health same utilit*) #8 #2 or #3 or #4 or #5 or #6 or #7 #9 #1 and #8 This retrieved 49 records.
Appendix 3 © Queen’s Printer and Controller of HMSO 2006. All rights reserved. Health Technology Assessment 2006; Vol. 10: No. 23 Excluded studies from the updated search (after the first screening) (n = 115) Reference Reason for exclusion Aggarwal and Lillystone, 2000160 Inappropriate population: co-morbid disorder Akhondzadeh et al., 2003 161 Unlicensed comparator/no placebo Akhondzadeh et al., 2004 162 Inadequate data presentation Allen, et al., 2001 163 Abstract only Allen, et al., 2002 164 Abstract only Aman and Langworthy, 2000 165 Inappropriate population: co-morbid disorder Aman et al., 2003 166 Inappropriate population: co-morbid disorder Baren et al., 2000 167 Abstract only Bedard, 2002 168 No relevant outcomes Bedard et al., 2004 169 No relevant outcomes Berman, 1998 170 Inadequate trial duration Berman et al., 1999 171 Inadequate trial duration Biederman, 2003 172 Inadequate trial duration Biederman, 2003 173 Abstract only Biederman et al., 2003 174 Inadequate trial duration Caballero and Nahata, 2003 175 Primary studies assessed for inclusion Chen et al., 2002 176 Unlicensed comparator/no placebo Chronis et al., 2003 177 No relevant outcomes Connor, 2002 178 Primary studies assessed for inclusion Connor et al., 2000 179 Inadequate data presentation Cox et al., 2004 180 No relevant outcomes Davidovitch et al., 1999 181 Inappropriate population: co-morbid disorder Denney and Rapport, 1999 182 No relevant outcomes Ding et al., 2002 183 Translation required Donnelly et al., 1989 184 Inadequate data presentation Duggan et al., 2000 185 Inadequate data presentation Ebell, 2002 186 Abstract only Eiland and Guest, 2004 187 Primary studies assessed for inclusion Firestone et al., 1998 188 Delayed receipt of paper Francis et al., 2001 189 No relevant outcomes Gadow et al., 1990 190 Inappropriate population: co-morbid disorder Gadow et al., 1999 191 Inappropriate population: co-morbid disorder Gadow et al., 2002 192 Inappropriate population: co-morbid disorder Gilmore and Milne, 2001 123 Primary studies assessed for inclusion Goldberg, 2002 193 Inappropriate population: co-morbid disorder Goldberg, 2002 194 Inappropriate population: co-morbid disorder Grcevich, 2003 195 Abstract only Greenhill, 2000 196 Abstract only Greenhill, 2000 197 Abstract only Greenhill et al., 1999 198 Inadequate data presentation (data not presented by drug) Greenhill et al., 2002 199 Inadequate data presentation (data not presented by drug) Gross-Tsur et al., 2002 200 Inappropriate population: co-morbid disorder Handen et al., 2000 201 Inappropriate population: co-morbid disorder Heiligenstein et al., 2002 202 Abstract only Heiligenstein et al., 2001 203 Abstract only Heiligenstein et al., 2001 204 Abstract only Heiligenstein et al., 2001 205 Abstract only Hoffman et al., 2003 206 Abstract only Jadad et al., 2000 207 Primary studies assessed for inclusion Kent, 1999 208 No relevant outcomes continued 171
Page 1 and 2: Appendices A systematic review and
Page 3 and 4: Clinical effectiveness information
Page 5 and 6: Searches for systematic reviews in
Page 7 and 8: 19. methyl phenidate.mp. 20. methyl
Page 9 and 10: 43. attention deficit$.mp. 44. 42 o
Page 11 and 12: MEDLINE in-process and other non-in
Page 13 and 14: PsycINFO (1967-July 2004) Searched:
Page 15 and 16: next aminopropane) or dynaphenyl or
Page 17 and 18: or ritaline or riphenidate or rital
Page 19: System for Information on Grey Lite
Page 22 and 23: 166 Appendix 2 S hyperkinetic S imp
Page 24 and 25: 168 Appendix 2 19. (eq5d or eq 5d o
Page 28 and 29: 172 Appendix 3 Reference Reason for
Page 31: Appendix 4 © Queen’s Printer and
Page 34 and 35: 178 Appendix 5 8. Was the statistic
Page 36 and 37: 180 Appendix 6 Cost-effectiveness R
Page 38 and 39: 182 Appendix 7 Appropriateness of m
Page 40 and 41: 184 Appendix 7 Sensitivity analysis
Page 42 and 43: 186 Appendix 7 Sensitivity analysis
Page 44 and 45: 188 Appendix 8 Probability cost-eff
Page 47 and 48: Appendix 10 © Queen’s Printer an
Page 49 and 50: Health state Responder to ATX, no s
Page 51 and 52: Health state Responder to IR-MPH, R
Page 53 and 54: Health state Responder to ER-MPH, R
Page 55: #Baseline shift random effects mode
Page 58 and 59: 202 Appendix 12 Study Intervention
Page 62 and 63: 206 Appendix 12 Core symptoms Educa
Page 76 and 77:
220 Appendix 12 Core symptoms Educa
Page 78 and 79:
Page 80 and 81:
Page 82 and 83:
Page 84 and 85:
228 Appendix 12 Study Intervention
Page 86 and 87:
Page 88 and 89:
Page 90 and 91:
Page 92 and 93:
Page 94 and 95:
Page 96 and 97:
Page 98 and 99:
Page 100 and 101:
Page 102 and 103:
Page 104 and 105:
Page 106 and 107:
Page 108 and 109:
Page 110 and 111:
Page 112 and 113:
Page 114 and 115:
Page 116 and 117:
Page 118 and 119:
Page 120 and 121:
Page 122 and 123:
Page 124 and 125:
Page 126 and 127:
Page 128 and 129:
Page 130 and 131:
Page 132 and 133:
Page 134 and 135:
Page 136 and 137:
Page 138 and 139:
Page 140 and 141:
Page 142 and 143:
Page 144 and 145:
Page 146 and 147:
Page 148 and 149:
Page 150 and 151:
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
Page 158 and 159:
Page 160 and 161:
Page 162 and 163:
Page 164 and 165:
Page 166 and 167:
Page 168 and 169:
Page 170 and 171:
Page 172 and 173:
Page 174 and 175:
Page 176 and 177:
Page 178 and 179:
Page 180 and 181:
Page 182 and 183:
Page 184 and 185:
Page 186 and 187:
Page 188 and 189:
Page 190 and 191:
Page 192 and 193:
Page 194 and 195:
Page 196 and 197:
Page 198 and 199:
Page 200 and 201:
Page 202 and 203:
Page 204 and 205:
Page 206 and 207:
Page 208 and 209:
Page 210 and 211:
Page 212 and 213:
Page 214 and 215:
Page 216 and 217:
Page 218 and 219:
Page 220 and 221:
Page 222:
366 Appendix 13 Study characteristi
show all

APPENDICES. A systematic review and economic model of the ...

Create successful ePaper yourself

Delete template?

Save as template?